foxo4-dri peptide senolytic 2023 2024 FOXO4/p53 – Peptagon Peptide inhibitors targeting FOXO4-p53 interactions

TME dynamically influences the progression of tumors and markedly impacts the outcomes of treatments

There is an urgent need for a long-term registry for these patients following them over several decades prospectively

Other long-acting GLP-1 analogues Other long-acting GLP-1 analogues are currently being investigated for weight loss in addition to diabetes treatment

While it's broadly deemed safe, some users may experience gastrointestinal upsets, occasional headaches, or skin irritations

However, a number of challenges will need to be addressed over next years including a better understanding of the full potential of benefits and risks with the new obesity pharmacotherapies and ensuring wide and equal access for people living with obesity

At ~504 Da molecular weight with only two amino acid residues (Tyr-Ile core), it falls below the typical size range of bioactive peptides